CAR-T cell therapy is one of the most promising treatments in a number of types of cancer. In myeloma, very promising results were presented during the American Society of Clinical Oncology (ASCO) Annual Meeting. Dr Hermann Einsele, Director of the Department of Internal Medicine II at the Würzburg University Hospital, summarises for Myeloma Patients Europe (MPE) the most important CAR-T cells updates in myeloma at ASCO 2020. Continue reading
The European Commission (EC) has approved isatuximab (Sarclisa®) in combination with pomalidomide and dexamethasone (pom-dex) for the treatment of adult patients with relapsed and refractory myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy. Continue reading
The largest, and one of the most important, oncology meetings in the calendar year, the American Society of Clinical Oncology (ASCO) annual scientific meeting, was held from 29 to 31 May.
Myeloma Patients Europe attended this virtual meeting and interviewed Dr Katja Weisel, University Medical Center Hamburg-Eppendorf in Germany, to summarise the most important myeloma highlights presented at ASCO20. Continue reading
From 29 to 31 May, the American Society of Clinical Oncology (ASCO) will hold its annual scientific meeting. This is the largest, and one of the most important, oncology meetings in the calendar year.
For the first time, ASCO20 will be held virtually adapting its programme and sessions to the COVID-19 situation. The programme will still feature over 250 oral abstract presentations and 2,500 poster presentations in 24 disease-based and speciality tracks. All presentations will be available on the ASCO20 website for a period of 180-days. Continue reading
Myeloma Patients Europe (MPE) held a webinar on personalised medicines in myeloma and AL amyloidosis given by Ellen Watters, Myeloma Information Nurse Specialist at Myeloma UK (MUK). Continue reading
Bristol Myers Squibb (BMS) and bluebird bio, Inc have announced that the companies received a Refusal to File letter from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for idecabtagene vicleucel (ide-cel; bb2121) for patients with heavily pre-treated relapsed and refractory myeloma, which was submitted in March 2020. Continue reading
Myeloma Patients Europe (MPE) will hold a webinar on the impact of myeloma and AL amyloidosis in carers on Wednesday 20 May 2020 from 18:00 – 19:00 CET.
The webinar will be given by Ellen Watters, Myeloma Information Nurse Specialist at Myeloma UK (MUK), who will give a 40-minute presentation followed by a 20-minute Q&A session.
Myeloma Patients Europe (MPE) held a webinar on personalised medicines in myeloma and AL amyloidosis given by Dr Francesca Bonello, Università degli Studi di Torino, in Italy. Continue reading
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval for daratumumab (Darzalex®) subcutaneous (SC) formulation for the treatment of adult patients with myeloma in frontline and relapsed/refractory settings. Continue reading
Myeloma Patients Europe (MPE) will hold a webinar on personalised medicines in myeloma and AL amyloidosis on Wednesday 6 May 2020 from 18:00 – 19:00 CET. Continue reading